tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alnylam price target raised to $255 from $250 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Alnylam to $255 from $250 and keeps an Equal Weight rating on the shares. The firm is largely in-line with consensus and expects Q2 TTR franchise revenues to be approximately flat quarter-over-quarter, the analyst tells investors in a small-to-mid cap Biotechnology group preview.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1